Literature DB >> 21176984

Feasibility of CBCT-based target and normal structure delineation in prostate cancer radiotherapy: multi-observer and image multi-modality study.

Carola Lütgendorf-Caucig1, Irina Fotina, Markus Stock, Richard Pötter, Gregor Goldner, Dietmar Georg.   

Abstract

BACKGROUND AND
PURPOSE: In-room cone-beam CT (CBCT) imaging and adaptive treatment strategies are promising methods to decrease target volumes and to spare organs at risk. The aim of this work was to analyze the inter-observer contouring uncertainties of target volumes and organs at risks (oars) in localized prostate cancer radiotherapy using CBCT images. Furthermore, CBCT contouring was benchmarked against other image modalities (CT, MR) and the influence of subjective image quality perception on inter-observer variability was assessed. METHODS AND MATERIALS: Eight prostate cancer patients were selected. Seven radiation oncologists contoured target volumes and oars on CT, MRI and CBCT. Volumes, coefficient of variation (COV), conformity index (cigen), and coordinates of center-of-mass (COM) were calculated for each patient and image modality. Reliability analysis was performed for the support of the reported findings. Subjective perception of image quality was assessed via a ten-scored visual analog scale (VAS).
RESULTS: The median volume for prostate was larger on CT compared to MRI and CBCT images. The inter-observer variation for prostate was larger on CBCT (CIgen=0.57±0.09, 0.61 reliability) compared to CT (CIgen=0.72±0.07, 0.83 reliability) and MRI (CIgen=0.66±0.12, 0.87 reliability). On all image modalities values of the intra-observer reliability coefficient (0.97 for CT, 0.99 for MR and 0.94 for CBCT) indicated high reproducibility of results. For all patients the root mean square (RMS) of the inter-observer standard deviation (σ) of the COM was largest on CBCT with σ(x)=0.4 mm, σ(y)=1.1 mm, and σ(z)=1.7 mm. The concordance in delineating OARs was much stronger than for target volumes, with average CIgen>0.70 for rectum and CIgen>0.80 for bladder. Positive correlations between CIgen and VAS score of the image quality were observed for the prostate, seminal vesicles and rectum.
CONCLUSIONS: Inter-observer variability for target volume delineation in prostate cancer is larger for CBCT-based contouring compared to CT and MRI. This factor of influence needs to be considered when defining safety margins for CBCT-based Adaptive Radiotherapy (ART).
Copyright © 2010. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21176984     DOI: 10.1016/j.radonc.2010.11.016

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  26 in total

1.  Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy.

Authors:  I Fotina; C Lütgendorf-Caucig; M Stock; R Pötter; D Georg
Journal:  Strahlenther Onkol       Date:  2012-01-27       Impact factor: 3.621

2.  Assessment of accuracy and efficiency of atlas-based autosegmentation for prostate radiotherapy in a variety of clinical conditions.

Authors:  I Simmat; P Georg; D Georg; W Birkfellner; G Goldner; M Stock
Journal:  Strahlenther Onkol       Date:  2012-06-07       Impact factor: 3.621

3.  Influence of the type of imaging on the delineation process during the treatment planning.

Authors:  Weronika Jackowiak; Bartosz Bąk; Anna Kowalik; Adam Ryczkowski; Małgorzata Skórska; Małgorzata Paszek-Widzińska
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-18

4.  Pelvic multi-organ segmentation on cone-beam CT for prostate adaptive radiotherapy.

Authors:  Yabo Fu; Yang Lei; Tonghe Wang; Sibo Tian; Pretesh Patel; Ashesh B Jani; Walter J Curran; Tian Liu; Xiaofeng Yang
Journal:  Med Phys       Date:  2020-05-11       Impact factor: 4.071

5.  Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration: interobserver agreement between radiation oncologists and therapists.

Authors:  B A Jereczek-Fossa; C Pobbiati; L Santoro; C Fodor; P Fanti; S Vigorito; G Baroni; D Zerini; O De Cobelli; R Orecchia
Journal:  Strahlenther Onkol       Date:  2013-08-17       Impact factor: 3.621

6.  A novel approach for establishing benchmark CBCT/CT deformable image registrations in prostate cancer radiotherapy.

Authors:  Jinkoo Kim; Sanath Kumar; Chang Liu; Hualiang Zhong; Deepak Pradhan; Mira Shah; Richard Cattaneo; Raphael Yechieli; Jared R Robbins; Mohamed A Elshaikh; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2013-10-31       Impact factor: 3.609

7.  Metal artifact correction for x-ray computed tomography using kV and selective MV imaging.

Authors:  Meng Wu; Andreas Keil; Dragos Constantin; Josh Star-Lack; Lei Zhu; Rebecca Fahrig
Journal:  Med Phys       Date:  2014-12       Impact factor: 4.071

8.  Delineation of the larynx as organ at risk in radiotherapy: a contouring course within "Rete Oncologica Piemonte-Valle d'Aosta" network to reduce inter- and intraobserver variability.

Authors:  Domenico Cante; Edoardo Petrucci; Cristina Piva; Valeria Casanova Borca; Piera Sciacero; Maurizio Bertodatto; Caterina Marta; Pierfrancesco Franco; Monica Viale; Giovanni La Valle; Maria Rosa La Porta; Oscar Bertetto
Journal:  Radiol Med       Date:  2016-07-15       Impact factor: 3.469

9.  Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.

Authors:  C Lütgendorf-Caucig; I Fotina; E Gallop-Evans; L Claude; J Lindh; T Pelz; B Knäusl; D Georg; R Pötter; K Dieckmann
Journal:  Strahlenther Onkol       Date:  2012-10-10       Impact factor: 3.621

10.  Prostate cancer: contouring target and organs at risk by kilovoltage and megavoltage CT and MRI in patients with and without hip prostheses.

Authors:  Lorenzo Falcinelli; Isabella Palumbo; Valentina Radicchia; Fabio Arcidiacono; Valentina Lancellotta; Giampaolo Montesi; Fabio Matrone; Claudio Zucchetti; Marta Marcantonini; Vittorio Bini; Cynthia Aristei
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.